Simplify Logo

Full-Time

National Field Training Manager

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$165k - $180kAnnually

Senior

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Sales
Marketing
Requirements
  • 50% Travel required
  • Applicants must be currently authorized to work in the United States on a full-time basis.
Responsibilities
  • Conduct regular field rides to ensure appropriate and effective execution and pull-through of training/marketing/sales initiatives
  • Aid the Director, Learning & Development, in the development of overall product training frameworks, programs, content, collateral, and rollout plans to increase sales force skills and knowledge with the goal of positively impacting sales results
  • Assist in the execution of all Commercial training programs, including but not limited to new-hire onboarding, product training, industry updates, competitive landscape reviews, and sales skill development to ensure the maximum effectiveness of the sales force
  • Facilitate workshops and training classes on subjects including, but not limited to, those listed above
  • Partner with Sales Management, and Regional Training Liaisons (RTLs) to assess training gaps and work one-on-one in the field with our Clinical Specialists to address those gaps
  • Assist in the planning and execution of National Field Meetings to align the Field Salesforce with current customer perspectives and Marketing brand goals
  • Facilitate ongoing distance learning programs in order to increase field competencies while minimizing time spent away from customers
  • Maintain a high level of business intelligence, including new training methods, training programs and best practices
  • Comply with all laws, regulations, and policies that govern the conduct of Corcept activities

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

7%

2 year growth

29%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.